Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years

Ann Oncol. 2018 Jan 1;29(suppl_1):i1-i2. doi: 10.1093/annonc/mdx724.

Authors

J Vansteenkiste¹, E Wauters¹

Affiliation

¹ Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospitals KU Leuven, Leuven, Belgium.

PMID: 29462258
DOI: 10.1093/annonc/mdx724

No abstract available

Publication types

Editorial
Historical Article
Introductory Journal Article
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / history*
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics
Gefitinib / history
Gefitinib / pharmacology
Gefitinib / therapeutic use
History, 20th Century
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Molecular Targeted Therapy / history
Molecular Targeted Therapy / methods
Mutation
Protein Kinase Inhibitors / history*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors
Gefitinib